314 related articles for article (PubMed ID: 30481683)
1. ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway.
Huang X; Yu P; Liu M; Deng Y; Dong Y; Liu Q; Zhang J; Wu T
Int Immunopharmacol; 2019 Jan; 66():236-241. PubMed ID: 30481683
[TBL] [Abstract][Full Text] [Related]
2. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
[TBL] [Abstract][Full Text] [Related]
3. Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway.
Di TT; Ruan ZT; Zhao JX; Wang Y; Liu X; Wang Y; Li P
Int Immunopharmacol; 2016 Mar; 32():32-38. PubMed ID: 26784569
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
5. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
Ma L; Xue H; Qi R; Wang Y; Yuan L
J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
[TBL] [Abstract][Full Text] [Related]
6. Hyperforin Ameliorates Imiquimod-Induced Psoriasis-Like Murine Skin Inflammation by Modulating IL-17A-Producing γδ T Cells.
Zhang S; Zhang J; Yu J; Chen X; Zhang F; Wei W; Zhang L; Chen W; Lin N; Wu Y
Front Immunol; 2021; 12():635076. PubMed ID: 34025642
[TBL] [Abstract][Full Text] [Related]
7. MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice.
OuYang Q; Pan Y; Luo H; Xuan C; Liu J; Liu J
Int Immunopharmacol; 2016 Oct; 39():369-376. PubMed ID: 27540765
[TBL] [Abstract][Full Text] [Related]
8. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.
Xu J; Duan X; Hu F; Poorun D; Liu X; Wang X; Zhang S; Gan L; He M; Zhu K; Ming Z; Chen H
J Dermatol Sci; 2018 Feb; 89(2):127-135. PubMed ID: 29137840
[TBL] [Abstract][Full Text] [Related]
9. Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Shokrian Zeini M; Haddadi NS; Shayan M; Shokrian Zeini M; Kazemi K; Solaimanian S; Abdollahifar MA; Hedayatyanfard K; Dehpour AR
Int Immunopharmacol; 2021 Nov; 100():108160. PubMed ID: 34583123
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.
Nadeem A; Al-Harbi NO; Al-Harbi MM; El-Sherbeeny AM; Ahmad SF; Siddiqui N; Ansari MA; Zoheir KM; Attia SM; Al-Hosaini KA; Al-Sharary SD
Pharmacol Res; 2015 Sep; 99():248-57. PubMed ID: 26149470
[TBL] [Abstract][Full Text] [Related]
11. Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice.
Mori H; Arita K; Yamaguchi T; Hirai M; Kurebayashi Y
Kobe J Med Sci; 2016 Sep; 62(4):E79-E88. PubMed ID: 28239073
[TBL] [Abstract][Full Text] [Related]
12. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice.
Liu Z; Liu H; Xu P; Yin Q; Wang Y; Opoku YK; Yang J; Song L; Sun X; Zhang T; Yu D; Wang X; Ren G; Li D
Biomed Pharmacother; 2018 Dec; 108():1425-1434. PubMed ID: 30372845
[TBL] [Abstract][Full Text] [Related]
13. Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.
Zhang M; Li N; Cai R; Gu J; Xie F; Wei H; Lu C; Wu D
Phytother Res; 2021 Aug; 35(8):4526-4537. PubMed ID: 34008239
[TBL] [Abstract][Full Text] [Related]
14. C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from γδ-T cells.
Zheng QY; Xu F; Yang Y; Sun DD; Zhong Y; Wu S; Li GQ; Gao WW; Wang T; Xu GL; Liang SJ
FASEB J; 2020 Aug; 34(8):10590-10604. PubMed ID: 32557852
[TBL] [Abstract][Full Text] [Related]
15. 2'-fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway.
Lei K; Wang D; Lin L; Zeng J; Li Y; Zhang L; Lane JA; Zuo D; Sun L
Int Immunopharmacol; 2020 Aug; 85():106659. PubMed ID: 32544868
[TBL] [Abstract][Full Text] [Related]
16. Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17.
Lin ZM; Ma M; Li H; Qi Q; Liu YT; Yan YX; Shen YF; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
Pharmacol Res; 2018 Mar; 129():443-452. PubMed ID: 29155016
[TBL] [Abstract][Full Text] [Related]
17. Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway.
Liu A; Zhao W; Zhang B; Tu Y; Wang Q; Li J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32515468
[TBL] [Abstract][Full Text] [Related]
18. Ferulic acid altered IL-17A/IL-17RA interaction and protected against imiquimod-induced psoriasis-like skin injury in mice.
Lo HY; Li CC; Cheng HM; Liu IC; Ho TY; Hsiang CY
Food Chem Toxicol; 2019 Jul; 129():365-375. PubMed ID: 31054998
[TBL] [Abstract][Full Text] [Related]
19. Decryption of Active Constituents and Action Mechanism of the Traditional Uighur Prescription (BXXTR) Alleviating IMQ-Induced Psoriasis-Like Skin Inflammation in BALB/c Mice.
Pang X; Zhang K; Huang J; Wang H; Gao L; Wang T; Sun Y; Chen L; Wang J
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933541
[TBL] [Abstract][Full Text] [Related]
20. Topical Application of BMS-509744, a Selective Inhibitor of Interleukin-2-Inducible T Cell Kinase, Ameliorates Imiquimod-Induced Skin Inflammation in Mice.
Otake S; Otsubaki T; Uesato N; Ueda Y; Murayama T; Hayashi M
Biol Pharm Bull; 2021 Apr; 44(4):528-534. PubMed ID: 33473072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
